chronic kidney disease
Endocrinology · 2020–2025
8decisions
3medicines
7carried consumer input
30individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dapagliflozin To reduce the risk of progressive decline in kidney function in adults with chronic kidney disease (CKD). | Sep 2025 | Recommended with restriction | input received |
| empagliflozin Extension of listing for chronic kidney disease to include additional patient subgroups with eGFR 20 to 90 mL/min/1.73 m², including those with eGFR <45… | May 2025 | Recommended with restriction | input received |
| empagliflozin Treatment of chronic kidney disease to reduce the risk of kidney disease progression in adult patients with eGFR 20 to <90 mL/min/1.73 m2 (with UACR ≥200 mg/g… | Nov 2023 | Recommended with restriction | 3 individuals |
| dapagliflozin Chronic kidney disease (CKD) with proteinuric CKD Stage 2, 3 or 4 and urine ACR ≥30 mg/g, to reduce the risk of progressive decline in kidney function. | Mar 2022 | Recommended | input received Kidney Health Australia · Diabetes Australia |
| dapagliflozin Treatment of chronic kidney disease in adults with eGFR ≥25 to ≤75 mL/min/1.73 m² and UACR ≥200 to ≤5000 mg/g, on stable maximum tolerated dose of ACEI or ARB. | Sep 2021 | Recommended with restriction | 9 individuals Diabetes Australia · Kidney Health Australia |
| dapagliflozin Treatment of chronic kidney disease (CKD) in adults with eGFR ≥25 to ≤75 mL/min/1.73 m², UACR ≥200 and ≤5000 mg/g, stable on maximum tolerated dose of ACEI or… | Jul 2021 | Deferred | 9 individuals Diabetes Australia · Kidney Health Australia |
| dapagliflozin Treatment of chronic kidney disease in adult patients with eGFR ≥25 to ≤75 mL/min/1.73 m² and UACR ≥200 to ≤5000 mg/g who are stable on a maximum tolerated… | Nov 2021 | Deferred | 9 individuals Diabetes Australia · Kidney Health Australia |
| whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, low in protein, phosphate, potassium and lactose for the dietary management of chronic kidney disease (CKD) in infants and young children | Mar 2020 | Recommended with restriction | none received |
Who spoke
Diabetes Australia · Kidney Health Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.